What changed?
A sourced timeline of research records and material development changes tracked by BACToBasics for Ipamorelin. Research-publication dates and clinical-development event dates are labeled separately so they are not mistaken for the same type of update.
Tracked items
3
Research sources
2
Development entries
1
Latest recorded date
Published 2026
Latest development activity
Dec 2009 · Program status · Phase 2 (historical)
ClinicalTrials.gov records the Phase 2 postoperative-ileus study as completed in December 2009. The program did not later become an FDA-approved ipamorelin product.
Open source ↗Latest research record by publication date
Published 2026 · Regulatory · Regulatory / safety review
FDA highlights unresolved safety concerns for compounded ipamorelin, including peptide characterization, immunogenicity, and limited route-specific human safety information.
Open source ↗Tracked timeline
Development changes are dated to the underlying milestone. Research-source entries use the study or source publication year currently stored in the Research Library; that year is not presented as the date BACToBasics added the record.
Regulatory · Regulatory / safety review
FDA highlights unresolved safety concerns for compounded ipamorelin, including peptide characterization, immunogenicity, and limited route-specific human safety information.
Program status · Phase 2 (historical)
ClinicalTrials.gov records the Phase 2 postoperative-ileus study as completed in December 2009. The program did not later become an FDA-approved ipamorelin product.
Human intervention · Human pharmacology
This direct human study demonstrated a short ipamorelin half-life and a distinct episode of GH release following administration.
Following a compound creates a clean baseline from the updates currently known. When BACToBasics later records a new research source or material development change, the My Tools update badge can surface it as new for you.
BACToBasics provides educational research organization only. A development milestone does not predict future approval, and a research record does not establish that a compound is safe, effective, approved, or appropriate for use.